Lexeo Therapeutics (NASDAQ:LXEO) Research Coverage Started at JPMorgan Chase & Co.
JPMorgan Chase & Co. initiated coverage on shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) in a research report report published on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $20.00 target price on the stock. Several other analysts also recently weighed in on LXEO. Stifel Nicolaus began coverage on Lexeo […]
More Stories
Head to Head Analysis: Iota Communications (OTCMKTS:IOTC) and Cass Information Systems (NASDAQ:CASS)
Cass Information Systems (NASDAQ:CASS – Get Free Report) and Iota Communications (OTCMKTS:IOTC – Get Free Report) are both computer and...
Short Interest in AngioDynamics, Inc. (NASDAQ:ANGO) Declines By 12.3%
AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) was the recipient of a significant decrease in short interest during the month...
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Large Increase in Short Interest
ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) was the recipient of a large increase in short interest during...
X-Links Crude Oil Shares Covered Call ETN (NASDAQ:USOI) Short Interest Down 19.5% in December
X-Links Crude Oil Shares Covered Call ETN (NASDAQ:USOI – Get Free Report) was the target of a significant drop in...
Short Interest in Ultralife Co. (NASDAQ:ULBI) Grows By 19.3%
Ultralife Co. (NASDAQ:ULBI – Get Free Report) was the recipient of a large increase in short interest in December. As...
Tyra Biosciences, Inc. (NASDAQ:TYRA) Short Interest Up 25.9% in December
Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) saw a significant increase in short interest in the month of December....